DSC Technologies

DSC Technologies (Louisville, KY) is developing a point-of-care blood plasma assay to distinguish between Type I and Type II heart attacks. Toponin biomarker assays are the current standard diagnostic, however several thousand patients are misdiagnosed each year with potentially dangerous ramifications.